{"schema_version":"secwatch.filing_event.v1","accession":"0001698530-22-000085","form_type":"8-K","ticker":"XCUR","cik":"0001698530","company_name":"EXICURE, INC.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.746209+00:00","generated_at":"2026-06-21T20:38:58.231894+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Exicure reports Q3 loss $5.2M; wind-down & going concern; $5.4M PIPE pending vote","bullets":["Net loss $5.2M vs $23.5M; revenue $2.0M vs $(3.7)M due to AbbVie collaboration adjustment.","Cash $16.8M (down from $48.3M Dec 2021); expects to fund into Q2 2023; substantial doubt about going concern; may need bankruptcy if PIPE fails.","Private placement with CBI USA: 3.4M shares at $1.60, ~$5.4M gross; CBI to hold 50.4% after close; shareholder vote Dec 15, 2022.","Company winding down preclinical programs, cut 66% workforce, suspended all R&D; seeking out-license for cavrotolimod and SCN9A program."],"urls":{"canonical":"https://secwatch.observer/filing/0001698530-22-000085","json":"https://secwatch.observer/filing/0001698530-22-000085.json","markdown":"https://secwatch.observer/filing/0001698530-22-000085.md","text":"https://secwatch.observer/filing/0001698530-22-000085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1698530/000169853022000085/0001698530-22-000085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1698530/000169853022000085/xcur-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:38:58.231894+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c40c889d5f3c5fd758770ec06ae9a34303683b34","claim":"EXICURE, INC. reported quarter ended September 30, 2022 results: revenue $2.0 million, net income $5.2 million.","evidence_excerpt":"proceeds from the Private Placement as the Private Placement has not closed) will enable it to fund its current operations into the second quarter of 2023. Revenue : Revenue was $2.0 million for the quarter ended September 30, 2022, reflecting an increase of $5.7 million from revenue of $(3.7) million for the quarter ended September 30, 2021. The increase in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1698530/000169853022000085/0001698530-22-000085-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Revenue","value":"$2.0 million"},{"label":"Net income","value":"$5.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}